F5 and COVID-19: Coagulopathy is an important cause of morbidity and mortality in patients with COVID-19, and a marked increase in circulating Factor V (FV) activity has been reported in patients with severe COVID-19, associated with increased risk of thromboembolism (Stefely et al., 2020).